Lv11
88 积分 2022-04-28 加入
FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments
2小时前
待确认
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
14天前
已完结
CD19-CAR T-cell therapy induces deep tissue depletion of B cells
14天前
已完结
Barriers to CAR T-cell therapy in rheumatology
14天前
已完结
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy
14天前
已完结
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
1个月前
已关闭
Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review
1个月前
已完结
An update on the pathogenesis of idiopathic inflammatory myopathies
1个月前
已完结
Idiopathic inflammatory myopathies: current insights and future frontiers
1个月前
已完结
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma
1个月前
已关闭
皖公网安备34019202002308
